Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of trifluridine/tipiracil plus ramucirumab as third-line or later treatment for advanced gastric cancer
jRCTs041210105Phase 2Active, not recruiting
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trifluridine + tipiracil and ramucirumab in gastric cancer (GC). Primary endpoint: Time to treatment failure. Started Feb 2022; status: active, not recruiting.
02
Drugs
trifluridine + tipiracilramucirumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on jRCTs041210105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041210105.